Terri has significant experience in a wide range of life sciences, synthetic biology, and clean technology industries that allows her to provide creative solutions and render pragmatic business advice to her clients. Her practice focuses on global patent strategy, creation of valuable IP portfolios, preparation and prosecution of patent applications, comprehensive portfolio management, freedom-to-operate analysis, opinion work, inter partes review (IPR) and other post-grant proceedings, and complex landscape searches and white space analysis.

Terri leads and conducts due diligences for both private and public companies and investors. She has been the primary IP counsel on many deals on behalf of investment bankers and underwriters for IPOs and other capital market offerings totaling more than $2 billion. Terri has also worked on company-side reverse mergers, public offerings, and mergers and acquisitions. She has also worked with private equity firms, hedge funds, and venture capitalists on due diligence assessment for investments and landscape analysis for formation of new funds and companies.

In addition, Terri’s practice includes assessing freedom-to-operate positions and rendering patentability and invalidity opinions. She has extensive experience in evaluating patent landscapes to advise clients seeking to enter competitive markets, as well as advising clients on third-party challenges and risk mitigation strategies. She has worked on biotechnology patent litigations, oppositions, and inter partes reviews.

Terri has worked on a wide variety of technical areas including antibodies, biologics and biosimilars, immuno-oncology (including chimeric T-antigen receptors and engineered immune cells), immunotherapy, cell therapy, gene editing (e.g., CRISPR technology), stem cells, regenerative medicine, gene therapy, synthetic biology, microbiomes, enzymes, protein engineering, protein production and therapeutics, vaccines and adjuvants, diagnostics and biomarkers, cancer, biofuels, microbial & yeast engineering, industrial fermentation, production of target chemical using biological processes, quantum sensors, biological computations units, and artificial intelligence / machine learning for life science applications, amongst other subject matters.

She has worked with emerging companies, universities, and larger companies. Representative matters include work done for Roche, Genentech, 10x Genomics, DuPont/Danisco/Genencor, Regeneron, Ariosa, the University of California, and Stanford University.

Terri was trained as an immunologist at Johns Hopkins School of Medicine, where her doctoral research focused on natural killer cells and the early immune responses to HIV and SIV infection. She was a student fellow with Nobel Laureates Dr. Joseph Goldstein and Dr. Michael Brown, researching farnesylated ras proteins.

Terri earned a certificate in artificial intelligence in pharma and biotech from MIT Sloan School of Management and a certificate in artificial intelligence in health care from Harvard Medical School.

Terri is in leadership positions at Mintz. She founded and is Chair of the firm’s AI Life Sciences IP Group. She also serves as Co-chair of the Minority Attorneys & Agents affinity group and serves on the Equity Advisory Committee and Women’s Initiative Steering Committee. Terri formerly served on the firm’s Policy Committee.

Terri has been consistently recognized as a leading patent practitioner, earning rankings in Chambers USA for Patent Prosecution from 2022 through 2026. In 2026, she was named to Forbes’ inaugural America’s Top Women Lawyers list and Forbes’ America’s Top Lawyers list. She was also recognized as Managing IP’s Patent Prosecution Practitioner of the Year in 2025 and LMG Life Sciences’ Patent Strategy Attorney of the Year (California) in 2023.

In addition, Terri was named among Managing Intellectual Property’s Top 250 Women in IP from 2022 to 2026, selected for the National Law Journal’s Intellectual Property Trailblazers list, and recognized as a finalist for the California Legal Awards 2025 Women Leaders in Tech Law: Intellectual Property. Her other honors include being named one of the “100 Most Influential Women in Business in the Bay Area” by the San Francisco Business Times, earning annual recognition in IAM Patent 1000 among the world’s leading patent practitioners, and being recognized in The Legal 500 United States for Healthcare: Life Sciences.